- Adamis Pharmaceuticals ( NASDAQ: ADMP ) has begun a review of strategic and financing alternatives that could include a sale of the company or its marketed products.
- Other potential options are a merger, reverse merger, and/or seek additional financing.
- Shares are up 7% in after-hours trading.
- Adamis has hired Raymond James as a strategic advisor.
- The company's two products are Symjepi (epinephrine) and Zimhi (naloxone) injections.
- In September, Adamis ( ADMP ) was dealt a major setback when its COVID-19 candidate Tempol did not achieve the primary endpoint in a Phase 2/3 clinical trial .
For further details see:
Adamis Pharmaceuticals considers sale of company as part of strategic alternatives review